Clinical trials: Colorectal Cancer Metastatic
Colorectal Cancer
Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)
Regorafenib in third-line treatment of metastatic colorectal cancer(mCRC) significantly prolongs the survival of patients, and its advancement has a sensitizing effect on postline chemotherapy and thus improves the prognosis of…
- Trial name
- NCT05818267
- Testing
- Regorafenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Wei Zhang
Colorectal Cancer Metastatic, MSI-H Colorectal Cancer
Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.
NIPISAFE is open-label, phase II study to identify a combination scheme of nivolumab and ipilimumab with a high level of clinical activity, but with a lower toxicity in MSI/dMMR metastatic colorectal cancer patients.
- Trial name
- NIPISAFE (NCT04730544)
- Testing
- Nivolumab 480mg + Ipilimumab, Nivolumab 240 mg + Ipilimumab
- Where
- 19 sites in France
- Volunteers
- 96 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Colorectal Cancer
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
The purpose of this study is to compare the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer.
- Trial name
- RECOURSE (NCT01607957)
- Testing
- TAS-102
- Where
- 115 sites in United States, Australia and 11 more
- Volunteers
- 800 people
- Sponsor
- Taiho Oncology, Inc.
Cognitive/Functional Effects, Colorectal Cancer
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
This randomized phase III trial studies how well combination chemotherapy plus bevacizumab with or without oxaliplatin works in treating older patients with colorectal cancer that has spread to other places in the body.
- Conditions
- Cognitive/Functional Effects, Colorectal Cancer, Neurotoxicity
- Trial name
- NCT01279681
- Testing
- bevacizumab, capecitabine, fluorouracil
- Volunteers
- 32 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Cancer Metastatic
Effect of Age, Body Mass Index and Tumor Sidedness in Metastatic Colorectal Cancer
To determine progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer in relation to age, BMI and tumor sidedness, describing their predictive influence on systemic therapy outcome.
- Trial name
- NCT04543019
- Volunteers
- 50 people
- Sponsor
- Assiut University
Rectal Cancer, Colon Cancer
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
In this Phase I/II clinical trial, the investigators seek to pilot the addition of hydroxychloroquine (HCQ) to the standard front-line therapy of colorectal cancer, FOLFOX/bevacizumab.
- Conditions
- Rectal Cancer, Colon Cancer, Metastasis, Adenocarcinoma
- Trial name
- NCT01206530
- Testing
- Hydroxychloroquine, Oxaliplatin, Leucovorin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Microsatellite Stable Metastatic Colorectal Cancer
Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
TORCH-M is a prospective, single-arm, two-cohort, investigator-initiated phase II trial to investigate the efficacy and safety of standard systemic therapy in combination with high/low-dose radiotherapy plus toripalimab in…
- Trial name
- NCT06525428
- Testing
- standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Fudan University
Liver Tumors
Freehand Ultrasound Elasticity Imaging in Liver Surgery
The purpose of this study is to investigate the potential for visualizing radiofrequency-induced (RFA) and microwave-induced (MWA) hepatic thermal ablation lesions using a novel, high resolution, and freehand ultrasound…
- Trial name
- IOUS (NCT00942383)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colon Cancer
Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer
This non-randomized phase II study is designed to assess the response rate and toxicity of weekly topotecan as second-line treatment in patients with relapsed or refractory metastatic colorectal cancer.
- Trial name
- NCT00193167
- Testing
- Topotecan
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- SCRI Development Innovations, LLC
Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer
EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options
The objective of this study is to improve the chemotherapy decision making process for Latinos with advanced gastrointestinal cancers.
- Conditions
- Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT03602885
- Testing
- Usual chemotherapy education (CE), Chemotherapy education intervention (CEI)
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Dana-Farber Cancer Institute
Colorectal Cancer, Liver Metastases
Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis
Trans arterial chemoembolization using Irinotecan Drug-eluting Beads before liver surgery for patients with primarily unresectable colorectal liver metastasis
- Trial name
- NCT04912258
- Testing
- Trans arterial chemoembolization with Irinotecan Drug-eluting Beads
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer
FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer
The purpose of the study is to evaluate if the exposure to all the three active cytotoxic agents (FOLFOXIRI regimen) is superior in terms of progression-free survival to conventional chemotherapy with the FOLFOX regimen as…
- Trial name
- NCT02128425
- Testing
- FOLFOXIRI, FOLFOX
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Sun Yat-sen University
Colorectal Adenocarcinoma
Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .
Multicenter prospective phase II study evaluating regorafenib in older patients with metastatic colorectal cancer
- Trial name
- REGOLD (NCT02788006)
- Testing
- Regorafenib 160 mg
- Where
- 16 sites in France
- Volunteers
- 43 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Metastatic Colorectal Cancer
The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal Cancer
This study aims to evaluate the safety and efficacy of Immuncell-LC, the adoptive immuntherapeutic agent composed of a CIK cell agent, to treat patients with metastatic colorectal cancer, which are refractory to the 3rd-line…
- Trial name
- NCT03220984
- Testing
- Immuncell-LC intravenous infusion using a CIK cell agent
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Gangnam Severance Hospital
Urinary Retention, Rectal Cancer
Effect of ICCAUT Strategy on Postoperative Urinary Retention After Radical Rectal Cancer Surgery (ICCAUT-2)
The objective of this trial is to investigate the effect of bladder training on the incidence of re-catheterization after proctectomy.
- Conditions
- Urinary Retention, Rectal Cancer, Urinary Catheterization
- Trial name
- NCT06217016
- Testing
- ICCAUT, Free drainage
- Where
- China
- Sponsor
- The First Hospital of Jilin University
Older Patients, Colorectal Cancer
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
The goal of this phase III, open-label, non-inferiority randomized controlled clinical trial is compare upfront dose-reduced chemotherapy with the standard dose chemotherapy in older patients ( ≥70 years) with metastasized…
- Conditions
- Older Patients, Colorectal Cancer, Metastatic Cancer, Candidates for Palliative Chemotherapy
- Trial name
- DOSAGE (NCT06275958)
- Testing
- Doublet Chemotherapy, Standard Dose (100%), Doublet Chemotherapy, Dose-reduced (75%), Monotherapy, Standard Dose (100%)
- Where
- 36 sites in Netherlands
- Volunteers
- 587 people
- Sponsor
- Leiden University Medical Center
Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)
A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)
This single-arm phase II trial enrolls patients with RAS-mutant, microsatellite-stable (MSS) unresectable colorectal cancer liver metastases receiving first-line treatment with Retlirafusp alfa combined with XELOX (capecitabine…
- Trial name
- NCT07797244
- Testing
- Retlirafusp alfa+XELOX+Bevacizumab Treatment
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Dai, Guanghai
The Characteristics of CRLM Patients Who Would Benefit More From Anatomical Resection
Anatomical Resection in Colorectal Liver Metastases Patients
The type of liver resection (anatomical resection, AR or nonanatomical resection, NAR) for colorectal liver metastases (CRLM) is subject to debate.
- Trial name
- NCT05673564
- Testing
- Anatomical Resection
- Volunteers
- 729 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
To determine if sorafenib when added to chemotherapy will slow disease progression more than chemotherapy alone in patients previously untreated for metastatic colorectal cancer.
- Trial name
- NCT00865709
- Testing
- Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
- Where
- 116 sites in United States, Belgium and 8 more
- Volunteers
- 198 people
- Sponsor
- Bayer
Metastatic Colorectal Cancer
Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer
Since its introduction, 5-fluorouracil (5-FU) has been the cornerstone of treatment for metastatic colorectal cancer (mCRC). Meanwhile the oral 5FU pro-drug Capecitabine (Xeloda®) proved equivalence to 5-FU and is a well…
- Trial name
- PASSION (NCT02119026)
- Testing
- Capecitabine, Bevacizumab, Oxaliplatin
- Where
- Austria
- Volunteers
- 120 people
- Sponsor
- Prof. Dr. Werner Scheithauer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.